Director Thomas J. Fallon of Hercules Capital, Inc. (NASDAQ:HTGC) acquired 7,300 shares of the company's common stock on March 26, 2026, at $14.30 per share, for a total transaction value of $104,390. At the time of the purchase the stock was trading close to its 52-week low of $13.70, with the most recent quoted price at $14.20.
The shares were purchased through the Fallon Family Revocable Trust. A footnote in the related SEC filing states that the transaction resulted from Fallon’s election to receive stock instead of cash compensation for his role as a director of Hercules Capital.
Following this buy, Fallon directly owns 5,959 shares and indirectly holds 157,669 shares through the Fallon Family Revocable Trust.
Hercules Capital currently presents investors with a dividend yield of 13.24% and trades at a price-to-earnings ratio of 7.6.
Separately, the firm provided preliminary estimates for its fourth quarter and year-end financial position, projecting net asset value (NAV) per share in a range of $12.10 to $12.16 as of December 31, 2025, up from a NAV per share of $12.05 reported on September 30, 2025.
In its portfolio-lending activity, Hercules amended a loan agreement with Savara Inc. to make available up to an additional $75 million in funding, contingent on FDA approval of the investigational therapy MOLBREEVI. That potential financing, when combined with a prior $75 million agreement with RTW, could supply Savara with meaningful capital to support its drug launch activities.
Market analysts and short-sellers have recently scrutinized Hercules Capital. Piper Sandler lowered its rating on the stock from Overweight to Neutral and cut the price target to $17.50 from $20.50, citing concerns related to the company’s 35% exposure to the software sector and potential vulnerabilities tied to artificial intelligence-related disruption.
A short report from Hunterbrook raised questions about how Hercules values its software-related debt and whether the dividend is sustainable, noting that 35% of the company’s loan portfolio is exposed to software debt. Hunterbrook Capital disclosed that it holds a short position on Hercules Capital while maintaining long positions in similar securities.
InvestingPro subscribers have access to comprehensive Pro Research Reports covering HTGC and over 1,400 US equities, providing actionable intelligence for informed investment decisions.
This article summarizes the disclosed insider transaction and recent company developments based on public filings and announcements. It presents the transaction mechanics, the director’s resulting holdings, Hercules Capital’s reported valuation metrics and NAV estimates, a borrower financing amendment, and recent market commentary including an analyst downgrade and a short report.